Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $51.75 million. The enterprise value is $47.73 million.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.63 million shares outstanding. The number of shares has increased by 3.20% in one year.
| Current Share Class | 10.63M |
| Shares Outstanding | 10.63M |
| Shares Change (YoY) | +3.20% |
| Shares Change (QoQ) | +2.11% |
| Owned by Insiders (%) | 12.91% |
| Owned by Institutions (%) | 41.58% |
| Float | 8.66M |
Valuation Ratios
The trailing PE ratio is 35.07 and the forward PE ratio is 40.58.
| PE Ratio | 35.07 |
| Forward PE | 40.58 |
| PS Ratio | 2.88 |
| Forward PS | 2.56 |
| PB Ratio | 5.17 |
| P/TBV Ratio | 5.92 |
| P/FCF Ratio | 19.03 |
| P/OCF Ratio | 19.03 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 30.08, with an EV/FCF ratio of 17.56.
| EV / Earnings | 32.23 |
| EV / Sales | 2.66 |
| EV / EBITDA | 30.08 |
| EV / EBIT | 33.03 |
| EV / FCF | 17.56 |
Financial Position
The company has a current ratio of 4.34, with a Debt / Equity ratio of 0.12.
| Current Ratio | 4.34 |
| Quick Ratio | 3.17 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.56 |
| Debt / FCF | 0.42 |
| Interest Coverage | 1,445.00 |
Financial Efficiency
Return on equity (ROE) is 16.29% and return on invested capital (ROIC) is 8.67%.
| Return on Equity (ROE) | 16.29% |
| Return on Assets (ROA) | 7.64% |
| Return on Invested Capital (ROIC) | 8.67% |
| Return on Capital Employed (ROCE) | 13.40% |
| Revenue Per Employee | $578,387 |
| Profits Per Employee | $47,774 |
| Employee Count | 31 |
| Asset Turnover | 1.52 |
| Inventory Turnover | 2.26 |
Taxes
In the past 12 months, Nephros has paid $27,000 in taxes.
| Income Tax | 27,000 |
| Effective Tax Rate | 1.79% |
Stock Price Statistics
The stock price has increased by +206.29% in the last 52 weeks. The beta is 1.47, so Nephros's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | +206.29% |
| 50-Day Moving Average | 4.93 |
| 200-Day Moving Average | 3.33 |
| Relative Strength Index (RSI) | 48.39 |
| Average Volume (20 Days) | 73,958 |
Short Selling Information
The latest short interest is 9,961, so 0.09% of the outstanding shares have been sold short.
| Short Interest | 9,961 |
| Short Previous Month | 6,580 |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.12% |
| Short Ratio (days to cover) | 0.13 |
Income Statement
In the last 12 months, Nephros had revenue of $17.93 million and earned $1.48 million in profits. Earnings per share was $0.14.
| Revenue | 17.93M |
| Gross Profit | 11.34M |
| Operating Income | 1.45M |
| Pretax Income | 1.51M |
| Net Income | 1.48M |
| EBITDA | 1.59M |
| EBIT | 1.45M |
| Earnings Per Share (EPS) | $0.14 |
Full Income StatementBalance Sheet
The company has $5.17 million in cash and $1.15 million in debt, giving a net cash position of $4.02 million or $0.38 per share.
| Cash & Cash Equivalents | 5.17M |
| Total Debt | 1.15M |
| Net Cash | 4.02M |
| Net Cash Per Share | $0.38 |
| Equity (Book Value) | 10.01M |
| Book Value Per Share | 0.94 |
| Working Capital | 8.24M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.72M |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.72M |
| FCF Per Share | $0.26 |
Full Cash Flow StatementMargins
Gross margin is 63.24%, with operating and profit margins of 8.06% and 8.26%.
| Gross Margin | 63.24% |
| Operating Margin | 8.06% |
| Pretax Margin | 8.41% |
| Profit Margin | 8.26% |
| EBITDA Margin | 8.85% |
| EBIT Margin | 8.06% |
| FCF Margin | 15.16% |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.20% |
| Shareholder Yield | -3.20% |
| Earnings Yield | 2.86% |
| FCF Yield | 5.25% |
Analyst Forecast
The average price target for Nephros is $6.00, which is 23.20% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 23.20% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Nephros has an Altman Z-Score of -7.91 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.91 |
| Piotroski F-Score | 6 |
